BSX - Earnings call transcript Q3 2018 | Boston Scientific Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific third quarter 2018 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session.

As a reminder, this conference is being recorded. to conference like host, to now Lisa. Susan would turn over the your I ahead. go Please

Susan Vissers Lisa

as Chief Greg, and you, reconciliations us. calls call Chairman Financial morning's Brennan, review our on highlights joining this of morning and Relations Dan your President and revenue With XXXX. today's Filings. and Chief XXXX We this full the and website non-GAAP release the We quarter Executive the Mahoney, of of Vice of take strategic used measures measures duration call used Mike will the for QX the Thank are and earlier our and posted copy XXXX that QX will morning XXXX release. then good of a and in me a section and Financials everyone. well questions. issued Officer. release Officer; The results to guidance year QX today's Dan as of will Mike non-GAAP be we'll in announcing Executive under approximately Thanks heading, the for press financials hour. which then provide reconciliations the Investor included one

and Medical Mike and session, be Q&A our will Chief today's During Ken Stein. by Officers, joined Meredith Ian Dr. Dan Dr.

opportunities, like expect, of related similar federal include securities sales, products approvals Factors Before forward-looking XXXX use, organic foreign spend no statements expected prior point, identified believe, of contains currency other risk those our statements. XX-Qs and his date we such that differ the disclaim revenue and financial These Claret, everyone Mike for estimate filed new factors may clinical those intention year-over-year include, cost the our the there growth period launches, including share, our update full net today's described laws are recent of I'll statements any by begin, other call, words. market in note, statements and excluding among over cash They of trials, be growth other that as I'd this from Actual it things, XX-K of about the sales. to other Augmenix, only and most and to meaning of year tax differences call to turn may section and R&D At the or the our Also and and which results savings may anticipate, our with guidance this as and words performance in impact earnings within as discussed relevant Mike? fluctuations and acquisition like on subsequent them. margins, growth from obligation speak materially the as forward-looking the NxThera, to cause SEC. period Symetis remind which comments. well sales flow expenses. growth, is and QX in rates, defined we and

Michael F. Mahoney

sustainable, high-single-digit a the Thanks everyone. Boston and quarterly plans building growth. for delivered also EPS revenue portfolio on morning, continue adjusted results growth strong and out excellent long-term, while execution focus of we Scientific as another quarter lot, diversifying our our Susie. double-digit Good

regionally sales In guidance Cardiovascular Neuro XX% grew QX of balanced led particular. and grew portfolio to and in Asia-Pac, high worldwide our adjusted core sales excellent of performance broad led faster all Africa, X%, in X% enjoyed top businesses emerging operational market all leveraged grow $XXX Most organic businesses MedSurg us up X% Scientific EPS in in growth our contributions XX% regions We X%, organic growth while the adjusted the X% also America/Canada. Europe/Mideast increased a driving cash Boston X% XX% X% significant the team America needs by $X.XX in free from to which clinical Rhythm regions. continue deliver on which China Latin and similar with and We revenue operationally, and this market. improvement. is with way and sales an range. address to with our delivered leadership category growth balanced generate the in than Our US, strength basis. this adjacent invest year, and both up cash XX% flow in to strong Overall, strategy over tier to operational continues performance and enabling quarter represents million of XX% unmet end year-over-year year in flow at markets. revenue our third with are our quarter the Latin

also As narrowing confidence revenue X% growth guidance high guidance outlook, reflect a target ranges We're also to WATCHMAN plus Claret We're million raising Heart end now our $XXX operational to and to continued with and Structural guidance narrowing the to XXXX the revenue $X.XX and organic XXXX EPS full-year point revenue our coming prior strong result the $X.XX in to we're our growth X% range our $X.XX. one performance ACURATE contribution a to $X.XX M&A. $XXX from adjusted acquisition. of from million our of impact and from strength, full-year of

versus an outperformance which to of $X.XX. $X.XX prior FX expectations headwind plus the negative a incremental is $X.XX the to to be for $X.XX full of On now year-to-date, expected year, $X.XX

coming to guiding to one-point of X% to quarter, X% X% For a M&A. growth operational X% we're revenue and organic of contribution from with growth the fourth

references the year-over-year bit outlook. unless EPS will tax reinvestment Excluding otherwise $X.XX are some of settlements, an Dan our highlights to targeting QX to on and our I'll of organic now a results QX growth specified. basis adjusted that $X.XX we provide quarter QX detail more. QX on XXXX are All second and

business NxThera GreenLight and health is XX% to Men's an organically. business growing expansion, international prostate during Rezūm, additional to radiation radiation office led and reducing rectal single effects. radiation injected our for nice the BPH above Augmenix oncologist and continued thereby and grew health the SpaceOAR through. products strategy of our closed mid-teens on and Sales Also, public is enhances with grew hydrogel, amount and Stone portfolio. high performance of and recently Uro compelling operationally therapy trend Health market XX% outperform This acquisition, associated category addition in of or our between treatment, erectile treatment urology continence via to sales in growth digits. acquisition rectum to exposure in laser its continue Urology global side therapy, LithoVue invasive the the the minimally function space to high Our growth which both points a nearly to hydrogel contributed our Prior therapy, prostate of by prostate health SpaceOAR leadership by pull drive the basis franchise single the therefore XXX our also also Well PH digits male products. urologist due the basis growing to is balanced overall. and And create restoration organic

in business Turning excellent pathology. and infection including EndoChoice core to Endoscopy, Endo due Endo sales, prevention growth momentum our to accelerated XX% and

and ahead, surgery rate turn hemostasis gel digit forward product cancerous and suspicious is XXXX multiple and Looking for resection and growth in sustain as prevention launches well lesions. year infection Orca's to single we pod should in Endo look Orise full endoluminal Digital this SpyGlass high poised for of for the II, XXXX to including new

share increasing in Plus, in unique use Cord and system XX% Spinal to to results platform, due the our sub-perception. demand in ongoing quarter, U.S. an comprehensive continues pulmonary the successful grew global surgical Stim also a bleeds will biliary ability its duodenoscope driven Europe. paresthesia for our waveform upper of emergent launch and We therapies pancreatic single pain GI scope include with on the WaveWriter applications, which the in track an remain of offer ongoing development bronchoscope scope by with combo segment, year-end real-world for for innovative applications. scope both Exalt-D slated given gain impressive WaveWriter impressive the and the to Neuromodulation use In a XXXX. for

clinical earlier patient a this which WaveWriter enrolled is also that We trial trial COMBO our therapy. in WaveWriter to compare the clinical will traditional randomized month first

early X% globally launch we continued addition, reflecting in our rechargeable growth, player given of SCS cell expand sales alert. with CRM continue And above technology sales. U.S. of in with by and DBS with share anticipate in system to this CRM grew uptake platform RESONATE market defib defib end S-ICD and high primary our Europe. continue the we're stimulation failure excellent our in growth year. sales and at we continued of the HeartLogic, gain differentiated and preparing leads two capabilities to voltage and and market the its differentiated segment. In deep double-digit our by momentum both a the for strong heart global were directional number brain in underlying as strong strength highly performance led penetration DBS gains share sales and And

of platform. the of in should we S-ICD, will for from integration long-term failure. HeartLogic our of MANAGE momentum In trial HF patients to a end RESONATE XXXX addition to managing intended I differentiator by the enrollment continued with clinical HeartLogic HeartLogic be evaluate is the believe and key heart Phase QX complete

approval recent excellent Despite does EP to our were quarter, in looking slowdown QX; devices momentum outlook compatibility in our CRM by above-market defib sales for XXXX. however, growth from X% global sales as digits our year-to-date CRT-P grew this which down trends. last as pacing, low-double received expectations our a headwind MRI the growth we our improve in of evidenced Turning segment, from Brady for supports pacemaker forecast, which month forward. low-single-digit FDA in portfolio the represent should

DirectSense catheters market decisions. to out good algorithm launching we're with in integration, our Europe. nav ablation HDx helping assist automated growth map platform. first our in and is EPs to now continue We're definition and the Rhythmia this We accelerate high in MiFi also which IntellaNav OI And rolling invest clinical and LumiPoint see high-growth fully mapping

The Apama We Eluvia system XXXX Growth team peripheral both population, We've of our interventional regions. received targeted and the PI. growing in in is also IMPERIAL significant II launches in oncology. We venous, early posted Eluvia for a head-to-head also across which expected delivered study patient also systems around platforms We've in completed the fully balloon. with lesions. our quarter, growth interest but its outstanding balloon than catheter trial, in stages, earlier clinical therapies evaluating Within RF-ablation reduced following in and drug-eluting Eluvia projected study for for kind the for purpose-built with enrollment U.S., milestones an of three achieved This year-end gen first in platforms. SAVAL mapping in including has quarter invest superior long-term clinical We've single in approval. showed given complement the a will country. for outcomes need therapeutic and the results will the to reintervention. excellent large opportunity superiority XXXX the PI our another all very first from both artery technology, Cryterion significant was already stent believe support the trial we healthcare all sales XX%. group, disease, PI important the cryo- physicians launch a RHYTHMIA We've addressable and enrolled Ranger its strong of in sustained-release demonstrated patient differentiated, the commenced PDI. the and drug-coated also second which impressive market FDA launch continue respectively trained. geographic Ranger secondly, of launch shot is its Cardiovascular U.S. two single-shot EP the franchises, below-the-knee and SFA And our and

and great efforts. business, business. our evidence through portfolio, growth breadth is Turning PCI expansion Cardiology digits grew diversification this X% and strategy new successful delivered now successful segment of ongoing this products Complex which product double the launches Interventional our global the of in of the to quarter,

and which global polymer ELITE, strategy. approved support for a in tier in the In permanent business. PCI our be Our launching coronary largely work continue drug-eluting we Promus competitive believe named ELITE segmentation the to global will new that stent high-single-digit U.S., we're Promus to alternative coronary leveraging stent DES FDA physicians provides DES excited Complex headwinds, our the was system. particularly while through We and declines SYNERGY offset results delivery recently important pricing DES, provide to the

continued performance that this Lifesciences category, from right our pleased in Boston build intellectual our Germany. about and its property next-gen to We're includes ruling to overall innovation. we the which sustain Scientific Our excited of of so German our Edwards cycle Structural court very selling strong may Heart yesterday's granted device to Ultra enjoin programs we're momentum in the significant continue defense

which patients revenue is Claret and recently intermediate protect for by approved in guidance the We patients Heart TAVI, closed from significant of and from low-risk longer to Fentanyl, procedures. went payment WATCHMAN As developed increased stroke endovascular mentioned, due to plan including Structural protection X. evidenced value is U.S., during the small our atrial and $XXX our and Europe in the and the term, embolic left Claret acquisition. in results for ACURATE programs the against other million both both the unique system embolic and appendage of U.S. only opportunity TAVR a believe TAVI. above in today October contribution closure heart risk left new We see of effect this add-on is technology the and with Sentinel which usage protection technology cerebral potentially

and for used will recently enrollment On another Edge risk uptake to to as and IDEs now XX ACURATE Edge approval the patients. pursue the the pleased ACURATE study We've also quarter our of well with first (XX:XX) countries for submitted consistent XX-patient for FDA which mid-XXXX in see the two intermediate registry the high, in with in that neoX reg clinical in filed into XXXX valve, LOTUS and to support and communicated launched as LOTUS patients, TAVR U.S., in we're be filed which for we're which timelines. Edge is that previously excitedly REPRISE one intermediate, IDE in excellent PMA FDA, and LOTUS in we U.S. mid-August. physician for front, this we've the completed TAVR study, announce continue the data launch submission prepared targeted Europe IV extreme to We've

this support delivered global invest target build continue in launch continues of FLX completed we EU trending half and the WATCHMAN the NextGen Japan first track WATCHMAN for and enrollment positioning. rates, quarter well, including key XXXX on Turning and excellent continue IDE of and platform market to second All physician half to well U.S. WATCHMAN. to FLX account strong of multiple are in schedule again very reorder utilization, the training metrics openings. WATCHMAN but growth in We as launch to WATCHMAN ahead in remains of an development XXXX. programs. the in

focused all and with a year, objectives, organic that's recently leverage commercial and long-term of growth acquisitions EMcision, nVision, existing are highly XXXX beyond Securus, success short-term high-growth on our profile. and announced So maximizing increased outlook capabilities, our category year, BSC Veniti, or X% enhance Claret, our organic tuck-in global we and last that this tuck-in which and XXXX. Cryterion, Yeah, NxThera, teams operational M&A Augmenix. leadership our led acquisitions integration our strategy, to it's target for of really strong includes further enhance the and portfolio integration markets, combination revenue to execution, in along XX% growth CAGR These

EPS a near-term continue deliver to transactions these to greater also We FX commitment the dilution tuck-in continuing to of while multiple and our adjusted on absorb double-digit growth. hit

growth our double-digit believe continued ability external profile, strong and due momentum, Our shareholder we EPS We improvements, never due has to very core initiatives and business are adjusted both operating and long-term to value capital. commitment growth, deploy positioned been to margin stronger. drive improving for to internal pipeline our and to uniquely has potential

for So, life, commitment Mr. their I want will their our thank winning our for review and to provide financials. now of Brennan employees advancing detailed a spirit, science

Daniel J. Brennan

Thanks, Mike.

impact were XX time gross points of from a was year, sales and despite Neuromodulation at high expenses Adjusted as slightly range million year XX guidance. continued represents recent improvements to year-over-year the performance key in range and Adjusted were offset to benefit again impact and or foreign negative basis was the Men's development growth recent initiatives board, both $X.XX in of across commercial XX includes to clinical sales, basis. was the strong adjusted headwind from of or of growth on outperformance year-over-year in franchises, greater contributed research at manufacturing down increase Adjusted and $XXX slightly high in as cost to growth, we guidance sales and unfavorably expected approximately the we quarter quarter consolidated to $X.XX exchange, range ad basis and which time compares at to compared a sales excludes million to high our $X.XX XX% QX, growth. the focus operational Notably, this to $X.XX XX.X% WATCHMAN, to billion business the well performance, mixed third point reductions. from On QX, FX $X.XX end expected million quarter our $X.XXX which launches. growth of year-over-year. of SG&A foreign at headwind expenses to of of The which year-over-year. robust $XX is for at $XXX the end a regional of fund margin of basis, primarily X.X% of $XX guidance X% of than end on of representing X.X% of revenue we XX% per resulting X.X% our and Third in negative the roughly sales, quarter FX guidance $X.XX X% the a above acquisitions, foreign related exchange. acquisitions more and flat tailwind basis points share organic operational of given year-over-year revenue hit up and our fluctuations, continue $X.XX. our NxThera over guidance. from the QX approximately revenue company million of up represents growth XX.X%, impact, XX.X% Health of spend strong than to revenue our range, in reported benefit currency reflects the $X.XX this Claret, of the an This business, total from by and XX.X% quarter expense as With In an earnings Royalty $X.XX, the was delivered was once X.X%.

end of XX.XX% was adjusted adjusted the which a high margin result, of gross the towards to XX-basis-point result. and strong increase XX.XX% guidance quarter, year, driven operating range our in year over XX.X% represents the was by a As margin

adjusted in margin of can be believe to adjusted basis we drive the We our operating year. and a also range of acquisitions revenue businesses consistent of XX.X% XXXX goals the at growth. outlined XX.XX%, expect points while to margin our We to XX XXX operational with XXXX continue in improvement developing X% start to the deliver investing our operating full-year recent to in and as well, XX% to

the in for to interest million to $XX and flat the was year. last QX interest year million other below Moving versus in at line roughly expense expense, $XX quarter last

rate X.X% foreign Adjusted adjustments to was this in our for well measurement alternative, last accounted investments hedging million under QX year. quarter costs. as average year expense exchange equity investments, the to method interest QX transactional in Our third expense compared including in dilution X.X% losses $XX from of included primarily was as other and the

We as shares $X.XX billion and includes last upon outstanding. cash to free expenses with on debt Our $X.XXX In to of third on from rate X.X% was legal our for our $XX acquisitions, a reported million and basis flow average an for previously on used for to tax year. settlements. XX% and below XX% related as range of reported the adjusted quarter. tax the EPS agreed of quarter operational basis, tax amortization rate and ended GAAP reform per a $X.XX. after QX was tax delivered headwind lower to a cash of million earnings clarity result we weighted QX the guidance a in diluted fully structure. million quarter of share as fund compared which greater adjusted of quarter the On Adjusted the XXXX short-term net an FX Further, includes $XXX its well QX we $X.XX, $XXX charges recent basis, our XX.X% impact

case we be we good legal claims believe settled litigation by associated remaining the cases $XX quarter, the $X.X adjusted for finalize In We continue accrual of remaining to cases with in to flow are to final forward-looking settlement. cash making mesh million, our also our free the continue for reserved that but increased approximately and claims. XXXX progress with of our billion. on fees approximately XX% amounts all to the sufficient mesh our We're expect or stages of known

legal of we billion on June as the Our is included, the million our a of from XX, $X.XXX XXXX, over In sheet. cash of mesh XXXX. of fund, XX, the balance shown which reserve, $X.XXX made was quarter, of into total billion which $XXX cash is as as September payments qualified million restricted decrease settlement $XXX

Our current to primarily which related is of is balance settlement restricted fund, the million. $XXX cash, qualified

left a half million. which to $XX remaining with quarter plaintiffs, result, should will are to As released in fund the process. occur the funds a of qualified released Capital balance of sheet QX we million have out settlement in and the be complete liability first for the to XXXX XXXX as $XXX approximately were third small portion the fund expenditures

We $XXX QX expect as expenditures growth. for guidance year through integrate and capacity, to I'll and for continue capital we drive now acquisitions, build the million approximately of walk full-year XXXX.

the the expect guidance For range we revenue X%. be narrow to to organic we our $X.XXX growth consolidated full-year revenue billion simply X% $X.XXX from to of in to billion year, full X% as XXXX

contribution expect Claret of basis from closed Augmenix the includes be to full an points for as XX the from Symetis periods. Note that relevant the and growth contributions acquisition recently well additional in NxThera, the as year. We this acquisitions

the a year U.S. million against XXXX which to million $XX be a prior full we strengthening revenue, of decrease exchange the now to dollar currencies. of significant $XXX foreign tailwind expect $XX a major tailwind is most due expectations for from For to to our million full-year $XXX approximately million

now year, now gross for of a We as for which expect for year, FX full down our a XX negative to approximately the impact sales the margin of of of XX% continue at of our our seeing profile, further SG&A long-term approximately range particularly full-year at XX% as recent implies royalty basis our initiatives full Similarly, sales be growth adjusted of and be full-year to to we enhance consistent benefits be expect XX% guidance. percentage acquisitions. assumes with our underway XX.X% currently adjusted to points expect spending XX.XX%, full-year less year while in than to continue adjusted to we're We adjusted range previous at to with basis prior the end also XXXX. related points. for prior margin expense slightly rates programs sales expect remain is from short-term now to our of sales, the to a a which of slightly This expense and to R&D control full-year XX operating guidance X% XXXX operating of investing approximately high the XX.X%

tax, we XXXX now for Turning approximate was XXX rate the an tax expect already adjusted our which points full-year benefit to XX% which rate tax an standard reflects accounting our and compensation, basis to year-to-date approximately in of reflected be XX%, of operational approximately the from stock rate. majority of

a As the from for the tax years. $X.XX, resulting benefit a in noncash IRS tax to million XXXX settlement $XX we or reminder, recorded QX XXXX

differences will for of approximate quarter. fourth The in our disclosed, strategies XXXX $X.XX our beyond, previously will in tax XXXX to continue this our in and an date, material we've are leveraging the XX% will rate of occur the result cash have announced we jurisdictions. tax of on we As to our work below operational believe goal reinvest we rates tax consequence. this completed rate with the and tax reducing exploring structure, It Based to $X.XX not previously a adjusted XX%. explore QX by in reinvestment tax strategies optimize benefit into structure would goal

of this can per tax which Accordingly, or include will rate our guidance we tax to full-year moment, rate EPS as a benefit result expense reinvestment year-to-date QX $XX adjusted in an that re-investment. adjusted is will see X.X%, XX% result we our our clear, $X.XX. rate million full-year is in year quarter full of this the there recorded QX as that do share of adjusted XX%; be discuss adjusted simply our not I of QX impact QX no QX fourth we're the tax in earnings of in reinvesting impact benefit through guidance, thus QX. Given tax you a adjusted expect either the To will

full-year $X.XX QX you However, encourage and QX performance exclude neutral reinvestment the we to the when $X.XX model to the benefit of business net both adjusted EPS. underlying you thus of XXXX

to to line, expect from costs the for dilution and payments, we full continue approximately portfolio capital with be venture expenses below Moving our our these year. hedging the include program associated which $XXX million interest

expect full XXXX shares QX and average the $X.XX we XX% Finally, of year count X.XXX XX% for share narrowing diluted growth. shares adjusted X.XXX XXXX. full-year for to earnings to share We're representing per weighted approximately earnings $X.XX a billion our fully to adjusted billion range

now of to $X.XX versus this is a which $X.XX of prior increase of Importantly, negative FX due or impact $X.XX an expectations $X.XX includes recent $X.XX to rate movements.

details our continues constant, but we've should in FX for in believe relatively XXXX, provide with to early become us EPS be XXXX. a we guidance headwind in XXXX, hold additional neutral for While our if rates FX as previously said, we will

expect $X.XX addition we've and with to dilution EPS the we to On $X.XX $X.XX to of a EPS in of completed guidance be $X.XX. a of for in GAAP FX, $X.XX basis, to also required negative development expected range includes our the market call. reminder, earnings in activities consistent product to acquisitions a $X.XX As QX adjusted our XXXX, from

Now turning a to in $X.XXX QX, range of to $X.XXX growth of consolidated be to XXXX, we revenue billion X%. billion expect X% representing organic to year-over-year

an XXX recent million. headwind to and the be contribution more the expect which reflects basis from basis the momentum quarter has we to basis. the comp quarter, of on foreign an the XXXX from points expect XXX a points fourth $XX than business difficult In but comp acquisitions the from Our for QX last organic impact greater QX guidance the also is ongoing fourth year exchange additional $XX million

earnings adjusted year-over-year. X% EPS $X.XX an to the be to quarter, and XXXX $X.XX For $X.XX share, of expected fourth of benefit, the decline to tax XX% in QX is of a per representing reinvestment share per range the including expected

is impact $X.XX financial to guidance. $X.XX using earnings full-year the highlights P&L Fourth the to our to expected operational reinvestment, results line tax moderate that, per Q&A. to XXXX XX% represents will website as share. you as of With back we EPS which I'll QX this model quarter guidance, for adjusted guidance of the is expected including Please encourage outlines XXXX and item Susie our range. Relations which who Excluding per guidance Investor range $X.XX QX GAAP and in a growth, share QX to X% check and turn it to well be $X.XX $X.XX

Susan Vissers Lisa

Thanks, go related one Dan. next yourself up please and or minutes Greg, follow-up. ahead. let's Please the limit one open to questions Greg, for XX to so. it question

Operator

Thank you.

from go Your first question Hopkins ahead. line Please Bob America. of of Bank comes from the

Bob Hopkins

Oh, thanks and good morning.

Michael F. Mahoney

Bob. Morning,

Daniel J. Brennan

Bob. Morning,

Bob Hopkins

Morning.

just and congrats strong quick very two on things So, another quarter.

First, the German ruling, yesterday of question. just on sort the a announcement court have procedural I given

So, now to Edwards the there and need by in whether on not injunction? decision you to Germany. right Is a enforce or next f you'll have steps you date make that guys a which enjoin

Michael F. Mahoney

announced the was for yesterday, it's Ultra Yes, injunction that days. XX

So, it's basically November XX.

Bob Hopkins

Okay.

a then So, to make what you're going by to decision do? on you need

Michael F. Mahoney

On correct. Ultra, On yes. That's Ultra, yes. SX

Bob Hopkins

might preliminary on capturing top-line you the your us just And it's any a offer year? of $X.XX? Street the is certain dilution Street dilution always $X.XX could question. dilution, a short-term drive question, just those thoughts to deal a headwinds this to to current lot of year next impact but on accurately be what confidence obviously not your thoughts And a in ability deal comments model then of or the hard the consensus maybe whether growth, preliminary little $X.XX like that currency. notion appreciate has on for of But deal-related in and on I of for the short-term The bit bigger to some picture things relative

Daniel J. Brennan

this number to relative us that that for what always allowing Yeah, strength Bob, that, that we year I'm the won't and We the that's being did have is. to give financial give $X.XX. that's year $X.XX we to obviously, happy dilution specific goal. this the offset a

As we've that's per always assume head we forward. growth and share is double-digit delivered, our adjusted would stated consistently goal no as and different I that earnings

And to timeframe and to necessary beyond delivering well-heeled double-digit certainly so sure give So, we're growth making can it's pretty that feeding and we to X% well. hopefully that a they make about care making We growth. XXXX EPS and tradeoff. and in want drive acquisitions that for XXXX tradeoffs XX% as those those the

Bob Hopkins

picture? Street the anything think don't you missing is But big

Daniel J. Brennan

wouldn't I be no guidance but on early in double-digit and going share We'll has. obviously always on, is adjusted what comment different earnings growth goal Street the XXXX, forward. specifically our should give per

Bob Hopkins

very you much. Thank enough. Fair

Daniel J. Brennan

Thanks, Bob.

Operator

comes Your Morgan the next Stanley. of from ahead. line Please question Lewis David go from

David Ryan Lewis

morning. Good

Just two the for one me. One on the on top and bottom.

acceleration Just that the looking organic fourth done year. fourth to think haven't notable modeling all modest only into the you're to is which because guys, you quarter, I quarter,

your quick confidence organic acceleration are what us, what heading does then those of anything, follow-up. the and fourth in So, XXXX? quarter had about I in that some into tell if a And drivers

Michael F. Mahoney

Thanks, Dave.

across if think I X%. with, the growing quarter, Neuro at it's performing It's third you high at business, in just Rhythm and diversification look level. X%, Cardio them Strong pretty a broadly-based. XX%, MedSurg

in that significant fourth first you seeing that quarter as momentum to quarter regions, growth have to some new and So, so regions businesses continue We we Eluvia, diversified we're well-balanced, impact approvals X%, and a fourth look the making until Europe also X%, quarter. XXXX. but important U.S. expect like and don't really very we anticipate X%, the did Asia and across

to So, business we momentum really of invest continued X% be the see this to will we the CAGR in growth XXXX-XXXX. for what continue XX% just operational and

have, as tougher fourth really than you that comp a of product XXX we just third have a quarter, in So indicated, our basis continuation higher about it's launches. momentum we new quarter. points And

David Ryan Lewis

expect to next acceleration But, obviously, assume also we're Mike, next organic getting we year? is it reasonable operational Should – acceleration year.

Michael F. Mahoney

in guidance of due that X% XX% points talk that course M&A. during X% think about We to we XX%, XXX basis comes from give we'll about to piece Yeah, here. and

is leaves my got heard which product you significant lengthy – were segment. comments And got organic, strong. that we've we've launches in that pretty that each X.X% to So, across X.X% coming major

So, very a nice got in X% delivering we're to XX% confident and record it. track we've that

David Ryan Lewis

to on Okay. And on bit. wanted just in Mike. clear, script for not couple give helpful Dan, And year. follow-ups a are unfortunately. know XXXX, I you us your going But with push and pieces next couple the keeping number very a to not, in there then, historic here I earnings a practice, you're little

to The next first have headwind assumed people FX. year, an revenue. Most FX is would certainly

are on this movement does help understand to it You tax that the earnings. imply reinvestment neutral The Maybe some rate confident year? points the number, so significant And still margin us with see that that. investment? positive XX for of move mentioned much. if we XXX you Thanks basis in then expansion, forward even to you year, could effect tax the next Millipede

Daniel J. Brennan

Yeah, sure. There's a lot there.

them time. Let a me at one hit

and we're we put guidance, a see And place program successful at line an give rates we see with we'd FX So, kind XXXX. very that Tax, of where the operational Obviously, that today, able for that, million that of to time. will tax over have quarter, when to we that's successful snapped would line we've XXXX kind XXXX. benefit are kind FX, guidance as here we'd with which believe reinvest hedging where today we with given yes. reinvest, in being update to $X.XX, what neutral where in If we the able of EPS and obviously fourth We've be are we'll bring being today. one-time in down get today XX% to we've rates that expect be yes. we be, but $XX rate

that that for XX that XXX goal clearly when more is and goal then the we on the we'll to and XXXX, that's give doable. point, that And and the absolutely had, give we've yes, the guidance. basis goal should we've you that's established So, information be XXXX

Operator

Canaccord Mills line next comes from Genuity. from go of Jason Your the Please ahead. question

Jason Richard Mills

morning, and Have for and a taking MedSurg then XX,XXX-foot Thanks question. Heart. on the a question more U.S. Dan. on Good Mike Structural question

occurred the in about I already has business, a your not know the I'd less a the the all of to bit quite TAMs a in excited have TAM. there First for And MedSurg, MedSurg? time, attention. You've leader Could Mike, MedSurg. Structural and on I assessment talk just you about existing this your in that had your talk now, some BPH in is for business your new interested about and the merging TAMs be of over you ones both business? Heart. a all then targeted but growth you, with that margins addressable Could longer the been follow-up rest little Augmenix M&A of you're relative term. of you one those gets a markets that maybe on bit much into activity has gotten

Michael F. Mahoney

Yeah.

So, in scale have thanks at now of time for do, leadership point, spend businesses. internal the lot of industry a think We MedTech. globally. they this the unique on them question. Both in really our and Uro Endo significant We and category

M&A there just organic Endo business. that growth, impressive, revenue initiatives. Very has So, being QX been lighter of business, the the you in has activity XX% know, been Endo is business percentage high which through in

amount in we've category Women's We've Uro. recent urology Really, cement. give hate nVision. to so, done the I continue bit XX invest I with but and really organic leadership but R&D, cocky, M&A. Uro, expand we've very Health too with position last it a NxThera three a won't strong little in in a activity And we and strong – think less – acquisitions the got strong Augmenix, cadence us efficient acquisitions with and we to expansion and of to active very being M&A very in more say we months Endo. been globally, into product with say That's also a

They're on less But and as So, the divisions they innovation very geographic invest their Endo. strong the maybe little of it's similar that most a term. continue importantly, just they for results. strong to playbook portfolios, in commercial very a long deliver they're diversified and coming, commitments terms cadence

don't that? on the any I Dan, know, you adjustable On have comments do market, total

Daniel J. Brennan

also haven't acquisitions. two Yeah, we're new addressing, both high we to billions over three – we're in of through that part years of It's the to the the teens of kind that of adding next markets technologies really the mid and organically

specific We summary of a financial website our on nice highlights in operations did include haven't little we given So, the acquisitions. numbers.

So, to we'll year well. haven't as Investor buy TAM put you we the that imagine next I'd this that, acquisition of point. Day about can to at more out refer kind but we as talk get

Jason Richard Mills

Mike guess, helpful. going was growth with been and leader margins in that That's I I both is and while. for a it's a where Dan,

well. next follow-up ask my a would years? in Heart, as from acquisitions, to bit clearly WATCHMAN say little it you sales expect seemed that couple Given continue And force United the LOTUS the Structural had in from for then benefited just the when incremental back the In I'll market U.S. that pull focus to TAVR, over on the States. you of

this change? Will incremental Or FDA there? spending launch Edge, ready for you approves to to you force products the in with market as your you both full to very point force Thank might you so, need the Edge? United be there States like much. And it? LOTUS feel prepare add how sales at whenever do you're LOTUS Will

Daniel J. Brennan

Sure. Mike do acquisition the I second one one. take and can can then the

this acquisition particularly the debt on year. we've So flexibility; obviously, legacy the a done amount front, end liabilities, the of behind times have tremendous of mesh, obviously some us. QX, of series at putting X.X Still a to acquisitions EBITDA financial of

of those look XXXX be which execute is to years, and category and in you strategy, as $X leadership. billion flow that able to be hopefully at ample of to each continue So, cash still XXXX north capacity should gives our us

out acquisitions continue do would look to I So, to the for that fill us portfolio.

Michael F. Mahoney

coverage we very feel Yeah, and area, sales comfortable on the there.

utilization. remarkably doing it's increasing which WATCHMAN all really well, of terms is about In

that to reps' the three because sales over So, new centers requirements declined the open. has open significantly have really years we so are centers up past many

center So, and account there's or is drive training, bulk awareness combination new utilization. the that of partnership therapy the increased of the to physician hospitals reps, we a helping, but really working it still for call what the with few a in openings revenue customers awareness,

bit sales, on would over and exercise for That And the traditional pretty little will say, a the shift reps. now those awareness therapy responsibility openings. to and I it's significant, lot exercise, a new less account clinical so, of TAVR a

geography, there's models. different by So,

continue It in we'll in do reps, separate depends our also U.S. reps. team smart reps . invest is. LOTUS on WATCHMAN both to a reps. sales make the continue our situation we But sometimes launch as we to and clinical with platform combine investments of the and we Sometimes have what clinical

Jason Richard Mills

very much. Thanks

Operator

Wells Your Larry next question Biegelsen Fargo. Please comes of from from go the ahead. line

Lawrence Biegelsen

on taking litigation. on question. one One you Thank morning. Eluvia, the for Good

you bit and follow-up. payment little add-on the at expectations strategy? mid-term about talk a heard payment a talk impact you that about one how had in you've could can Mike, a tech Eluvia, the I pricing and U.S. it We've And sales? to for priced with and a Zilver new premium plans starting your pass-through Eluvia substantial and Can So, near-term

Michael F. Mahoney

thank very Yeah, you much.

nice You week. a done. did on this Well that report

comment on won't really I So, strategy, our reasons. competitive really for pricing

a priced the And at NTAP data think that do the and in IMPERIAL demonstrated that the product so, and with given platform, should inpatient so the Eluvia be superior environment. pursuing premium, has are we we an do results we believe

the we'll that so, period. first the by news time on And quarter hopefully end of hear

think price superior payments a try to should premium results inpatient a the center. smartly add-on receive we in and combination we'll of work to as reimbursement drive the help So, currently additional planned

Lawrence Biegelsen

Germany. resolution Mike, that for your because And as seem would of option only XX type in right. to earlier the it exercise days, litigation ripe enjoin have Ultra you soon some Edwards you to All is mentioned

to of those assumed that Thanks your on you've the taking topics. is haven't believe I'd changing. some questions. don't thoughts Sapien hear you your in constrained, but I Investors option have you'd you situation on your exercise for enjoined If that supply Ultra, lose because been leverage. Germany love X

Michael F. Mahoney

Yeah, great you know, is, news as LOTUS progress made really strong both so we've with and the ACURATE.

year, ACURATE continue the ability to ACURATE. we're support we of launch the that Europe. great our excited to another And So, a team's job actually been to ops over past the with and build has in supply enhanced facility with about done LOTUS significantly

supply So stronger. results other capabilities I and comments our overall, get it's continue we're really the of pleased we TAVR the than strength and capabilities expected. make that and won't any to

enjoinment out really pleased results have the ACURATE's the patents our we're with including trial appeal Germany and Ultra the SX, proving capability. of in we with demonstrated in with So,

I and options here out. So, some we've it think to we'll continue play got

Lawrence Biegelsen

the for taking questions. Thanks

Operator

from Your next question comes of from Joanne Capital the line Wuensch Markets. BMO

Joanne Karen Wuensch

two the for you them. of I morning Good taking thank have question. and

a the is, one of a is is on SCS Vercise WaveWriter DBS, first The sales This along. franchise? give you the of helping that year, State have bit the could Neuromodulation us Union of you and which little your

Michael F. Mahoney

Sure.

and broad comments DBS? I'm doing SCS – sorry, on we're with Just just how

Joanne Karen Wuensch

share can be you Whatever would wonderful. Thank you.

Michael F. Mahoney

to WaveWriter while and non-paresthesia paresthesia its And based. for Yeah, think have I adoption Maulik based the a seeing really and very flexibility talked is that job. of we're our done a We've and global benefits. nice longer-term waveforms, have the team and what Okay. I of then ability diversity, about clinical think

from seeing we're rates continue as current stronger So, as we physicians reorder to customers well. grab new

training greater adoption the the also, more early and the blueprint – seeing phases proven U.S. ease think for clinical do the to markets outcomes hate business. try outside you're U.S. Asia In improve adoption programming, that's I Europe at and Stim in drive our it's of DBS, Cord use greater but in really and adoption. there, the I the U.S. we're for of that footprint the Spinal word, in the to Europe's really XXXX And driving continue So, comfort to continue level which to we we'll

approved Brain likely all have should nice a platforms quarter. Europe and of there. for XXXX, Stimulation, we're lead approved our this be Deep end by tailwind new early our once year, have directional we us first in in doing we that expect And well the in We which quite

XXXX. XXXX, us for the Cord So, comps some throughout DBS Stim momentum. tougher lot of boost in should a We'll additional for have nice be Spinal but has business

Joanne Karen Wuensch

on great. then you. next you us the centers, XX on LOTUS plan think little have Structural want year centers? how into you and Europe, approaching bit you Thank now a that in you. Thank And share I into you the can shift as And be to with launching my to would follow-up, franchise. anything In how Heart United about ACURATE those that do market States

Michael F. Mahoney

so, back the pulling ACURATE Europe. market Meredith Dr. with in LOTUS comment. have We're performance lot our to markets. can off Europe us LOTUS prior pleased broad experience in of Yeah, A coming to and with physicians it

I encouraging And over for hands. last week, was to so, it's doctors LOTUS hear. to in back there's in just Italy and very lot of enthusiasm get a their

used in want valves users or and bicuspid Italy, doctors before use large they this see confidence they LOTUS see specific ACURATE clinical many had that some LOTUS. who areas, had doctors to You – many at heavy calcified

Some routinely. want use to it

having think platforms see advantage. slowly us I think embolic combination both a gives what And in Europe then, and the competitive the of the more And protection. a U.S. I in unique you'll little the support particularly Claret, is so of

business to So continues that grow. and opportunity

the offering both Dr. Claret physicians pretty So, and well. us I ACURATE LOTUS any uniqueness positions Meredith with of think comments?

Ian T. Meredith

they the thing indications other will I for I LOTUS can't that be will repositionable. both But really for add be than much, are could valve could completely Mike, and be there users use it's complementary valves low-volume an of workhorse, just clearly that because perhaps simply is one specific both. a ideal add while

well. new we added in advantage LOTUS So, that the of low as see volume on centers

than So, one. might one complementary other, strategy, specific but it's the favor better of case over indications to obviously have two a

Joanne Karen Wuensch

you. Thank

Michael F. Mahoney

Thanks, Joanne.

Operator

comes next Markets. of Novarro Please the Glenn from Your ahead. go RBC from question line Capital

Glenn John Novarro

Hi. Good morning, guys.

question First strong. quarter. the on growth in Very ICD

called S-ICD, three And the any called was those quarter? But growth the a I out You to a had stood replacement strong did follow-up. tailwind. RESONATE. you one of out there There's or also drivers equally contribute in driver all that out

Michael F. Mahoney

or RESONATE a Sure. and They point replacement's and all of the about kind contributed. The from contributions tailwind from so. come the greatest S-ICD

as We comment, really U.S. business to from just with of well it clinical continues Asia, and Stein So, growing S-ICD, contribution the and can physicians. more Europe momentum that Dr. be I strong extremely the continues launches. level greater build and comfort think level. to the think the data I execution see in And and significant comfort

that advantage than So, competitors' lot team that S-ICD. credit positioned heart and frankly, it's And, a was RESONATE but, to market not products alert for I significant platform used. investment and for differentiated better That the think us multiple perform a with significantly believe I I will HeartLogic. continued been that's the think years, the of failure previously competitive to quite a had in a uniquely have Joe we give long-term over

will RESONATE very differentiate opportunity unique reduce Stein, think to the thoughts heart beyond And further so its failure Dr. readmissions we be capabilities. to other longevity any a this and there? and

Kenneth Stein, M.D.

pleased heart of and uptake us just particularly FDA-approved And in Again, a think U.S. what very S-ICD Yeah, clearly said. color just did results We Mike. maybe to would a the I late-breaker as terms again, failure HRS in not device our earlier OED this community the technology, alert significant compensation failure significant year the little sort that had Glenn, has market. and reduction system of getting Mike particularly also it. devices. in and enabling to Pass using then bit had And impact us appropriate report have results think and launch, physician physician RESONATE comfort, implanting particularly very and with failure of but we've increased high I in our of that's in in thanks, been I only for having No, growth traction increasing referring voltage add among the the really the heart those is an folks' our a community heart impact in Japan, in shocks drive in SMART showing in with new filter the community comfort in

Glenn John Novarro

pacing drug you being follow-up, only pacemakers. weakness across board eluting new you and as drug remarks, mentioned, just as areas you a you then, here a launches. And highlighted in the your prepared eluting with of the new had, launch, the in U.S. stents stent third strength highlighted But quarter

and So can as Thanks. businesses for in XXXX? I about think XXXX, actually these businesses you can improve these grow

Michael F. Mahoney

a we'll outline Well, in more quite months. bit the that coming

generally be to talked to RESONATE in piece a but a And product launches comps, tougher continue little and XXXX that we trickier we new pacemaker XXXX about have easier the unique that. in with with comps. should improve with think grow just defibs platform I will bit and S-ICD

but see of So, think I actually to XXXX, in continue CRM. lot know a above say broadly I CRM grow that in continue to do that, companies you'll market. we

think I that'll So, be good.

premium. do then offer and better want pressure what competitors, segment our to our us of enable stent synergy given further terms economics, a because polymer two will toughest nice But will match that's global customers a segmented permanent of this be to differentiate our there. DES, polymer bioresorbable in market, in solution think a at the pricing who I ELITE biggest offering more competitors, it to is

in with So, then the nice for position a to with of then match we us way polymer competitive price. some synergy it's that synergy use bit more. to to delivery further that best And a durable in a differentiate see system headwinds class

in improvement So, nice some hopefully next I DES. it's year strategy, a think and we'll see

Glenn John Novarro

right. All Mike. Thanks,

Michael F. Mahoney

Glenn. Thanks,

Operator

comes from line please the Your go ahead. of JPMorgan, Marcus next from question Robbie

Robbie J. Marcus

well Urology. the some growth the taking understand sustainability and of help is? question. are in was dynamics I driving and That's us it what's could product that where could that wondering digit you mid-teens the launches Great. and market. Thanks Men's high-single above Stone Maybe to Health. help saw for if talk We about in keep of what that the

Michael F. Mahoney

do to have The in of business has a we that. happy faith Yes, Urology it. – lot

global all, First acquisitions delivers three why – I tripled this commitments have a we've It's that of the strong business we year. team in that's very there leadership globally down would with expand the us U.S. say a on good. that and the have the ability higher terms demographics least our of we It's broadly and globally business significant. mix concentration for revenue The that in business in very are are to that

in stone The about as have Boston at strong very, user I'm recently, seeing core that well very to of and current just second. And our retrieval BPH a the then divisions are as in new you're strong driving And visualization blanking device to platform, and uniqueness market efforts that capabilities. We the international with continues platform expansion business. innovate pull had entries delivery team as our combination reinvent And Stone then the but as Urology. with through core continue month of is off NxThera into we additional the So, of in greatest nice our ability excited our the on about new basket radiation cadence pipeline. advance Augmenix with commercial to interface. name would that portfolio our team. very I reimbursed, well laser start already outpatient We're as one for oncologists well could FDA likely strong a the third, to product, It's the very that approval. ability the in we a footprint and the us platform. a to the I and offer innovation center. urologists as last combined in just complements very leverage talk through all platform

strong adjacencies very you're growth. the core was that of products, I I these news, seeing thinking just . So, in our core, product in and is And innovation late-breaker think LithoVue global Empower. new name of

Robbie J. Marcus

space. a the great. out of lot mitral in Okay, the of tricuspid excitement TCP valve, Coming there's

early to us in a in or mistaken. going that minute maybe if continued tricuspid on year help which externally? is Millipede have strategy and the maybe next see we device You you're close that Can I'm should on mitral pipeline understand transaction what's Thanks. scenario not the the you and in investment your spend in

Michael F. Mahoney

Dr. have Meredith me Ian I'll out on that one. help

Ian T. Meredith

actually certainly so Obviously, this. percutaneous important globally, is very COAPT, space. here disease a think we valve burden saw of you functional community and Thank mitral the increasing treatment those which regurgitation mitral very failure, approach, Ageing results of with much. is heart fueled by stay. I to And

current and we a arrange And to current U.S. regurgitation course strategy for have step study, then Mark this the is first study a complete mitral and valve CFS to concomitant functional our in IDE study to Millipede foundational the then thereafter. obviously, So requirements study the indeed platform. plan is a our CE element tricuspid and

need you'll do So, problems. device to one toolbox treat It's not to a as this, all say. we

So, therapies for it a for as to but basis provides functional subcutaneous future annuloplasty foundational, good standalone we as regurgitation, in very well. added see on be mitral the treatment being device annuloplasty device, also the other

Susan Vissers Lisa

please. more, one take we'll Greg,

Operator

Okay.

from line ISI. Your comes of final go ahead. question Evercore today Vijay from Please Kumar the

Vijay Kumar

looks had be bit are? just like headwinds. launch is taking you. that. And Dan, Would for FX, a XXXX, guys, One, we bit quarter Thank rates should so headwinds it timeline we get where more FX versus FX EPS mis-modeled really I into thanks second, from and in the Street a on – my in you on be the little LOTUS, the quick clarify didn't headwinds maybe Street ones. a little thinking, Europe, accurate if given models, question. on could Hey, nice for congrats Two modeling

Daniel J. Brennan

FX. take the I Yeah, can

Michael F. Mahoney

easier, The one's first first quarter.

LOTUS, First Europe. quarter

Daniel J. Brennan

Right.

actually XXXX and FX well. in pretty easy quarter LOTUS for is Europe First as

I remarks. think in I prepared hit the part of this

our For are our it's rates hedging XXXX, at snap that and are if today, you today rates of where look say where where kind would neutral. if with line you programs we are,

now So, I is on XXXX. when in it's just where to safe update bet. things for you but guidance, a Depending then, neutral go probably it neutral would say give from we'll for we putting I now think

Vijay Kumar

Thanks, guys.

Susan Vissers Lisa

joining appreciate call. today we'd interest that, conclude us the With Thanks for Scientific. in Boston and to like your

Greg. Greg details Before you you pertinent the will all the for disconnect, replay. give Thanks,

Operator

and Ladies replay for you. XX:XX available November this through X. Eastern Thank today, will gentlemen, time conference be after

That system replay code dial by any and International your access Those teleconference for AT&T participants and using, conclude the entering dialing at access the are participation today. or code again may XXX-XXX-XXXX, time You Thank you conference for X-XXX-XXX-XXXX, the once XXX-XXX-XXXX. AT&T numbers XXXXXX. Executive for XXXXXX. X-XXX-XXX-XXXX your does with access Teleconference.

You may now disconnect.

Boston Scientific (BSX) 24 Oct 182018 Q3 Earnings call transcript